Hau Giang Pharmaceutical (DHG Pharma)
Vietnam's biggest domestic generic drug maker, licensed factories and nationwide distribution.
On the record
Checkpoint: New Japan/EU-GMP Betalactam plant comes fully online, testing whether DHG holds hospital-tender share
The call
DHG stays profitable and dominant on licenses and distribution, but grows slower than foreign-backed peers racing into the same antibiotics and hospital markets.
DHG Pharma makes generic medicines in Vietnam and sells them through 34 branches to 30,000+ customers. It is hard to replace because it has government licenses, certified factories, and a long-built distribution network that foreign drug companies would rather buy than build from scratch (which is exactly what happened when a Japanese company, Taisho, bought half of DHG). The real question is whether smaller Vietnamese rivals backed by foreign money, like Imexpharm with backing from a Chinese company, will steal market share in antibiotics and hospital drugs over the next few years, especially since DHG is paying out most of its profits as dividends instead of spending heavily to stay ahead in those segments.
Why
01
AI pressure: None apparent. Generic drug manufacturing and regulated distribution stay outside AI disruption for now. Could AI do the core job? Unlikely.
02
Bigger players: Imexpharm (Livzon-backed), Domesco (Abbott-controlled), Bidiphar, Traphaco (Daewoong/Mirae Asset). Foreign-backed domestic rivals are investing faster in antibiotics and hospital tenders, the segments DHG's new plant targets. Could a giant copy it? No, they are blocked.
03
What protects it. Ministry of Health approvals, GMP-certified plants, and a 34-branch, 30,000-customer distribution network rivals cannot copy fast.
What would change this call
DHG's revenue growth rate versus Imexpharm's and Bidiphar's growth rate in FY2026-2027 results. Shows whether foreign-backed rivals are outgrowing DHG in shared segments.
Whether DHG's new Japan/EU-GMP Betalactam plant reaches full output and wins hospital tenders by 2027. Tests if DHG can defend antibiotics/hospital share against Imexpharm.
Any announcement of Taisho taking DHG private or increasing its stake beyond 51%. Would signal a shift in capital allocation away from dividend-heavy strategy.
Whether DHG's new Japan/EU-GMP Betalactam plant reaches full output and wins hospital tenders by 2027. Tests if DHG can defend antibiotics/hospital share against Imexpharm.
Any announcement of Taisho taking DHG private or increasing its stake beyond 51%. Would signal a shift in capital allocation away from dividend-heavy strategy.
Key numbers
- FY2025 revenue VND 5.27 trillion, up 7.82% YoY
- Taisho owns 51.01%, SCIC owns 43.31%
- H1 2026 net income VND 298.67B vs VND 236.89B prior year
Named risks
- Foreign-backed domestic peers reinvesting faster may erode antibiotics and hospital-tender share once Betalactam plant is online, 2026-2027.
- Dividend-heavy payout (60-75%) limits capital available for reinvestment versus faster-growing rivals.
- Potential Taisho decision to take DHG private or restructure ownership structure.
- Policy reversal on Vietnam's domestic-sourcing preference (Group 1/Group 2 rules) could weaken DHG's structural advantage.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Imexpharm | contesting | Livzon-backed EU-GMP antibiotics maker overlapping DHG's new Betalactam plant, noted 2026-07-20 |
| Domesco | contesting | Abbott owns ~51.7% of Domesco, foreign-capital backing, per bizhub.vietnamnews.vn, 2026-07-20 |
| Traphaco | gaining on | Daewoong/Mirae Asset tech-transfer partnership; peer profits rising alongside DHG, 2025-08-05 |
| Bidiphar | gaining on | Oncology and hospital-channel momentum contrasted with DHG's 'steady' label, 2026-07-20 |
Questions people ask
- Is DHG Pharma profitable in 2026?
- Yes. DHG posted FY2025 net income of VND 824.78 billion, up about 9.3% YoY, and H1 2026 net income of VND 298.67 billion versus VND 236.89 billion a year earlier, reported July 20, 2026 via marketscreener.com.
- Who owns DHG Pharma (Hau Giang Pharmaceutical)?
- Japan's Taisho Pharmaceutical Co., Ltd. is the controlling shareholder with 51.01% as of mid-2025, while Vietnam's state investment arm SCIC holds 43.31%, per DHG's Corporate Governance Report dated July 30, 2025.
- Could AI replace DHG Pharma's business?
- Unlikely soon. DHG's moat rests on GMP-certified factories, Ministry of Health drug registrations, and a 34-branch physical distribution network reaching over 30,000 customers, none of which AI software can substitute; only back-office sales/forecasting tasks are AI-exposed.
- Who is DHG Pharma's biggest competitor?
- Imexpharm, an EU-GMP antibiotics maker backed by China's Livzon Pharmaceutical, directly overlaps DHG's new Betalactam plant segment; Domesco (51.7% Abbott-owned) and Bidiphar are also cited as faster-growing rivals as of July 2026.
- Is DHG Pharma growing its revenue?
- Yes, modestly. FY2025 revenue reached VND 5.27 trillion, up 7.82% from VND 4.88 trillion in FY2024 (which had declined 2.60%), per stockanalysis.com data dated July 3, 2026.
- Does DHG Pharma pay dividends?
- Yes, heavily. DHG paid 75% cash dividends for 2023 and 2024, then 60% for early 2025, reflecting a dividend-focused capital allocation strategy rather than aggressive reinvestment, per theinvestor.vn, May 13, 2025.
Timeline
- 2026-07-20Q2/H1 2026 earnings reported; Fujimori appointed Deputy GD Finance and Supply Chain effective May 1, 2026
- 2025-07-30Corporate Governance Report confirms Taisho 51.01% and SCIC 43.31% stakes
- 2025-05-13DHG announces 60% cash dividend and pivot toward direct end-consumer marketing
- 2025-01DHG's Technical Director resigns
- 2024-06-03DHG discloses VND 700 billion Japan/EU-GMP Betalactam factory investment
- 2022Construction begins on new Betalactam antibiotics factory
- 2019Taisho increases stake to controlling above 51%
- 2016-07-06Taisho Pharmaceutical acquires 24.5% of DHG for about $97 million
Revision history
26 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- DHG Pharmaceutical JSC Company Profile & Executives - WSJ (2026-02-13)
- Vietnam's major pharma firm DHG to pay 60% cash dividend (2025-05-13)
- DHG Pharmaceutical Joint Stock Company (DHG.VN) Company Profile
- BỘ TÀI CHÍNH - DHG Corporate Governance Report 1H2025 (2025-07-30)
- Japan's Taisho buys nearly 25% stake in Vietnam's DHG Pharma for $97M (2016-07-06)
- DC Advisory - Taisho dual-stage acquisition
- DHG Pharmaceutical JSC (HOSE) Revenue (2026-07-03)
- DHG Pharmaceutical Reports Earnings Q2/H1 2026 (2026-07-20)
- DHG 2020 Annual Report (2021-07-19)
- DHG Pharmaceutical JSC (HOSE) Employees (2025-12-30)
- Vietnam's leading pharma firm DHG plans 75% dividends for two consecutive years (2024-06-03)
- DHG Pharmaceutical JSC (HOSE) (2026-07-03)